Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab

Bibliography

• GREAVES MW, WEINSTEIN GD: Treatment of psoriasis. N Engl. I Med. (1995) 332:581–588.
   PubMed Web of Science ®Google Scholar
• GUENTHER LC, ORTONNE J-P: Pathophysiology of psoriasis: science behind therapy. I Caton. Med. Surg. (2002) 6(3 Suppl.):2–7.
   Google Scholar
• CAMISA C: Psoriasis: a clinical update on diagnosis and new therapies. Cleve. Clin. J. Med. (2000) 67:105–119.
   PubMed Web of Science ®Google Scholar
• KRUEGER GG, FELDMAN SR, CAMISA C et al.: Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?' Am. Acad. Dermatol (2000) 43:281–285.
   PubMed Web of Science ®Google Scholar
• KRUEGER G, KOO J, LEBWOHL M, MENTER A, STERN RS, ROLSTAD T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol (2001)137:280–284.
   PubMed Web of Science ®Google Scholar
• FLEISCHER AB, FELDMAN SR, RAPP SR: Introduction. The magnitude of skin disease in the United States. Dermatol Clin. (2000) 18:xv-xxi.
   Google Scholar
• KOO J: Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Berm. Clin. (1996) 14:485–496.
   Web of Science ®Google Scholar
• LEBWOHL M, FELDMAN SR,WALTHER R, SHELK J, MORGAN, P, GUTKIN SW: Clinical management of psoriasis: principles and practice. Cutts. (2001) 67(1 Suppl.):1–15.
   Google Scholar
• ••Overview of traditional psoriasis therapies.
   Google Scholar
• TRISTANI-FIROUZI P: Efficacy and safety of treatment modalities for psoriasis. Cutts. (1998) 61:11–21.
   PubMed Web of Science ®Google Scholar
• WEINSTEIN GD, WHITE GM: An approach to the treatment of moderate to severe psoriasis with rotational therapy. J. Am. Acad. Dermatol. (1993) 28(3)454–459.
   Google Scholar
• MUELLER W, HERMANN B:Cyclosporin A for psoriasis. N Engl. I Med. (1979) 301:555.
   PubMed Web of Science ®Google Scholar
• JEFFES EW 3RD, MCCULLOUGH JL, PITTELKOW MR et al.: Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells tothe cytotoxic and growth-inhibitory effects of methotrexate. J. Invest. Dermatol (1995) 104:183–188.
   Google Scholar
• GOTTLIEB SL, GILLEAUDEAU P, JOHNSON R et al.: Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. (1995) 1:442–447.
   PubMed Web of Science ®Google Scholar
• MOREL P, REVILLARD JP, NICOLAS JF,WIJDENES J, RIZOVA H, THIVOLET J: Anti-CD4 monoclonal antibody therapy in severe psoriasis. J. Autoimmun. (1992) 5:465–477.
   PubMed Web of Science ®Google Scholar
• WEINSHENKER BG, BASS BH, EBERS GC, RICE GP: Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. I Am. Acad. Dermatol (1989) 20:1132–1133.
   PubMed Web of Science ®Google Scholar
• RAYCHAUDHURI SP, DUTT S, RAYCHAUDHURI SK, SANYAL M, FARBER EM: Severe combined immunodeficiency mouse-human skin chimeras: a unique animal model for the study of psoriasis and cutaneous inflammation. Br. I Dermatol(2001) 144(5):931–939.
   PubMed Web of Science ®Google Scholar
• KIRBY B, GRIFFITHS CEM: Novel immune-based therapies for psoriasis. Br.! Dermatol (2002) 146:546–551.
   PubMed Web of Science ®Google Scholar
• ••Review of biological agents for psoriasisand their mechanisms of action.
   Google Scholar
• SINGRI P, WEST DP, GORDON KB: Biologic therapy for psoriasis: the new therapeutic frontier. Arch. Dermatol (2002) 138:686–688.
   PubMedGoogle Scholar
• ••Review article on the biological agentsbeing developed for psoriasis and their mechanisms of action.
   Google Scholar
• DUSTIN ML, SPRINGER TA: Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Ann. Rev Immunol (1991) 9:26–66.
   Google Scholar
• ROTHLEIN R, DUSTIN ML,MARLIN SD, SPRINGER TA: A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. I Immunol (1986) 137:1270–1274.
   PubMed Web of Science ®Google Scholar
• DUSTIN ML, STAUNTON DE, SPRINGER TA: Supergene families meet in the immune system. Immunol Today (1988) 9:213–215.
   PubMedGoogle Scholar
• ••Review of cell adhesion molecules and theirfunction in T cell adhesion and activation.
   Google Scholar
• FISCHER A, DURANDY A,STERKERS G, GRISCELLI C: Role of theLFA-1 molecule in cellular interactions required for antibody production in humans. J. Immunol (1986) 136:198–203.
   Google Scholar
• SPRINGER TA, DUSTIN ML, KISHIMOTO TK, MARLIN SD: The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system [review]. Ann. Rev Immunol (1987) 5:223–252.
   PubMed Web of Science ®Google Scholar
• WERTHER WA, GONZALEZ TN, O'CONNOR SJ et al.: Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. 1 Immunol (1996) 157:4986–4995.
   Google Scholar
• NICKOLOFF BJ, BASHAM TY, MERIGAN TC, MORHENN VB: Keratinocyte class II histocompatibility antigen expression. Br. J. Dermatol (1985) 112:373–374.
   PubMed Web of Science ®Google Scholar
• NICKOLOFF BJ: The role of gamma interferon in epidermal trafficking of lymphocytes with emphasis on molecular and cellular adhesion events. Arch. Dermatol (1988) 124:1835–1843.
   PubMed Web of Science ®Google Scholar
• KRUEGER JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol(2002) 46:1–23.
   PubMed Web of Science ®Google Scholar
• GRAKOUI A, BROMLEY SK, SUMEN C et al: The immunological synapse: a molecular machine controlling T cell activation. Science (1999) 285:221–227.
   PubMed Web of Science ®Google Scholar
• ••Review of the immunologic synapse and itsrole in T cell activation.
   Google Scholar
• HILDRETHJE, AUGUST JT: The human lymphocyte function-associated (HLFA) antigen and a related macrophage differentiation antigen (HMac-1): functional effects of subunit-specific monoclonal antibodies. I Immunol(1985) 134:3272–3280.
   PubMed Web of Science ®Google Scholar
• DOUGHERTY GJ, HOGG N: The role of monocyte lymphocyte function-associated antigen 1 (LFA-1) in accessory cell function. Eur. Immunol (1987) 17:943–947.
   PubMed Web of Science ®Google Scholar
• KRUEGER J, GOTTLIEB A, MILLER Bet al.: Anti- CD1 la treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J. Invest. Dermatol (2000) 115:333.
   Google Scholar
• LOWE J, STEFANICH E, RANGELL L, PIPPIG S: Efalizumab (anti-CD1 la) inhibits transendothelial migration of T cells. Poster presented at Society ofInvestigative Dermatology Los Angeles, California, May 15–18 (2002).
   Google Scholar
• BAUER RJ, DEDRICK RL, WHITE ML, MURRAY MJ, GAROVOY MR: Population pharmacokinetics and pharmacodynamics of the anti-CD1la antibody hu1124 in human subjects with psoriasis.' Pharmacokinet. Biopharm. (1999) 27:397–420.
   PubMedGoogle Scholar
• DUMMER W, JOSHI A, BEYER J et al.: Pharmacodynamic effects of subcutaneous (SC) administration of efalizumab (anti-CD11a). 60th Annual Meeting of the American Academy of Dermatology New Orleans, LA, Feb 22–27 (2002).
   Google Scholar
• GOTTLIEB A, KRUEGER JG,BRIGHT R et al.: Effects of administration of a single dose of a humanized monoclonal antibody to CD1 la on the immunobiology and clinical activity of psoriasis.' Am. Acad. Dermatol (2000) 42:428–435.
   Google Scholar
• PAPP K, BISSONNETTE R,KRUEGER JG et al.: The treatment of moderate to severe psoriasis with a new anti-CD1 la monoclonal antibody.' Am. Acad. Dermatol (2001) 45:665–674.
   Google Scholar
• GOTTLIEB AB, KRUEGER JG, WITTKOWSKI K, DEDRICK R, WALICKE PA, GAROVOY M: Psoriasis as a model for T-cell-mediated disease. Immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11 a antibody.' Am. Acad. Dermatol (2002) 138:591–600.
   Google Scholar
• GOTTLIEB AB, MILLER B, CHAUDHARI U et al: Clinical and histologic effects of subcutaneously administered anti-CD1 la (hu1124) in patients with psoriasis. Poster presented at Society of Investigative Dermatology Chicago, Illinois, May 10 (1999).
   Google Scholar
• KRUEGER J, GOTTLIEB AB,aMILLER B, DEDRICK R, GAROVOY M, WALICKE P: Anti-CD1 1 a (hu1124) treatment for psoriasis concurrently increases circulating T cells and decreases plaque T cells, consistent with inhibition of cutaneous T-cell trafficking. Poster presented at Society of Investigative Dermatology Chicago, Illinois, May 10–14 (2000).
   Google Scholar
• LEONARDI CL, GOTTLIEB AB, MILLER B, TASHJIAN D, PARISER D, SHAPIRO W et al.: Efalizumab (anti-CD1 la): results of a 12 week trial of subcutaneous administration in patients with moderate to severe plaque psoriasis. Poster presented at American Association ofDermatology Washington DC March 2–7 (2001).
   Google Scholar
• LEONARDI C et al.: Efalizumab (RaptivaTm) — an overview. Am. Acad. Dermatol (in press).
   Google Scholar
• ••Phase III data (safety and efficacy) forpsoriasis patients treated with efalizumab.
   Google Scholar
• BOYD AS, MENTER A: Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients." Am. Acad. Dermatol (1989) 21:985–991.
   Google Scholar